Open AccessImplications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first‐line therapy
Author(s) -
Wainberg Mark A,
Mesplede Thibault
Publication year - 2015
Publication title -
journal of the international aids society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.724
H-Index - 62
ISSN - 1758-2652
DOI - 10.7448/ias.18.1.20824
Subject(s) - dolutegravir , medicine , emtricitabine , drug resistance , resistance mutation , lamivudine , integrase inhibitor , virology , regimen , drug , clinical trial , pharmacology , protease inhibitor (pharmacology) , reverse transcriptase , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , virus , biology , genetics , hepatitis b virus , rna , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom